DE602004012117D1 - Neue zusammensetzungen von sildenafil-freier base - Google Patents

Neue zusammensetzungen von sildenafil-freier base

Info

Publication number
DE602004012117D1
DE602004012117D1 DE602004012117T DE602004012117T DE602004012117D1 DE 602004012117 D1 DE602004012117 D1 DE 602004012117D1 DE 602004012117 T DE602004012117 T DE 602004012117T DE 602004012117 T DE602004012117 T DE 602004012117T DE 602004012117 D1 DE602004012117 D1 DE 602004012117D1
Authority
DE
Germany
Prior art keywords
free base
sildenafil
new compositions
sildenafil free
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004012117T
Other languages
English (en)
Other versions
DE602004012117T2 (de
Inventor
Tuula A Ryde
Douglas C Hovey
H William Bosch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharma International Ltd
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Publication of DE602004012117D1 publication Critical patent/DE602004012117D1/de
Application granted granted Critical
Publication of DE602004012117T2 publication Critical patent/DE602004012117T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004012117T 2003-07-23 2004-07-23 Neue zusammensetzungen von sildenafil-freier base Active DE602004012117T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48910103P 2003-07-23 2003-07-23
US489101P 2003-07-23
PCT/US2004/019106 WO2005013937A2 (en) 2003-07-23 2004-07-23 Novel compositions of sildenafil free base

Publications (2)

Publication Number Publication Date
DE602004012117D1 true DE602004012117D1 (de) 2008-04-10
DE602004012117T2 DE602004012117T2 (de) 2009-02-26

Family

ID=34135095

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004012117T Active DE602004012117T2 (de) 2003-07-23 2004-07-23 Neue zusammensetzungen von sildenafil-freier base

Country Status (8)

Country Link
US (1) US20050042177A1 (de)
EP (1) EP1658053B1 (de)
JP (1) JP4860469B2 (de)
AT (1) ATE387186T1 (de)
CA (1) CA2533163A1 (de)
DE (1) DE602004012117T2 (de)
ES (1) ES2302035T3 (de)
WO (1) WO2005013937A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
CA2475092C (en) * 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CN1758930B (zh) 2003-03-27 2010-06-09 株式会社新日本科学 鼻腔用粉末药剂喷药装置
JP2007517803A (ja) 2004-01-05 2007-07-05 テバ ファーマシューティカル インダストリーズ リミティド シルデナフィル塩基とクエン酸塩の製造方法
EP1753429A1 (de) 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulatoren von muscarinischen rezeptoren
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
NZ555719A (en) * 2004-12-31 2010-11-26 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
AU2012201630B8 (en) * 2004-12-31 2014-03-06 Iceutica Pty Ltd NanoParticle Composition(s) and Method for Synthesis Thereof
WO2006074443A2 (en) * 2005-01-07 2006-07-13 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
EP1888037A2 (de) * 2005-05-10 2008-02-20 Elan Pharma International Limited Clopidogrel-nanopartikelformulierungen
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CA2610448A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
BRPI0611075A2 (pt) * 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
EP1954253A4 (de) 2005-06-08 2011-07-27 Elan Pharma Int Ltd Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit cefditoren
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
BRPI0611626A2 (pt) * 2005-06-13 2010-09-21 Elan Pharma Int Ltd formulações da combinação de nanopartìculas de clopidogrel e aspirina
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
WO2007027612A2 (en) * 2005-08-29 2007-03-08 Teva Pharmaceutical Industries Ltd. Solid particulate tadalafil having a bimodal particle size distribution
CA2622200A1 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
EP1956906A4 (de) 2005-11-09 2009-12-30 Combinatorx Inc Verfahren, zusammensetzungen und kits für die behandlung von medizinischen beschwerden
EP1968705A1 (de) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmazeutische kombinationen eines pde-5-hemmers und eines 5-alpha-reduktase-hemmers
EP1984344B1 (de) 2005-12-29 2012-09-26 Lexicon Pharmaceuticals, Inc. Multicyclische aminosäurederivate und verfahren ihrer anwendung
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP2009538927A (ja) 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド ナノ粒子状のポサコナゾール製剤
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008008733A2 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
MX2009007742A (es) * 2007-01-22 2009-07-27 Novavax Inc Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
EP2268265A2 (de) * 2008-03-21 2011-01-05 Elan Pharma International Limited Zusammensetzungen zur situsspezifischen abgabe von imatinib und anwendungsverfahren
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
NZ595986A (en) 2009-04-24 2014-04-30 Iceutica Pty Ltd A novel formulation of indomethacin
EP2429495A4 (de) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd Intranasale pharmazeutische zusammensetzung mit verbesserter pharmakokinetik
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
WO2010146407A1 (en) * 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011056916A1 (en) 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
JP2013519673A (ja) 2010-02-10 2013-05-30 レクシコン ファーマシューティカルズ インコーポレイテッド 転移性骨疾患の治療のためのトリプトファンヒドロキシラーゼ阻害剤
AU2011264941B2 (en) * 2010-06-07 2014-10-16 Suda Ltd Oral spray formulations and methods for administration of sildenafil
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102127182B (zh) * 2010-12-23 2012-07-04 南京医科大学 用于检测pde-5抑制剂的磁性分子印记聚合物的制备方法
WO2012108738A2 (ko) * 2011-02-11 2012-08-16 주식회사 씨티씨바이오 실데나필 유리염기 함유 필름 제제 및 이의 제조 방법
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
CA2918291C (en) 2013-07-22 2022-12-06 Universite Du Quebec A Chicoutimi Use of plant extracts against herpes simplex virus
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
KR101778688B1 (ko) 2016-05-31 2017-09-15 한양대학교 에리카산학협력단 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제
WO2018142189A1 (en) 2017-02-02 2018-08-09 Dukebox Sp. Z O. O. A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
SG11202006080SA (en) 2017-12-26 2020-07-29 Ftf Pharma Private Ltd Liquid oral formulations for pde v inhibitors
GR1009643B (el) * 2018-06-25 2019-11-12 Arvo Μονοπροσωπη Ι.Κ.Ε. Νεες συνθεσεις φαρμακευτικων σκευασματων σιλδεναφιλης μειωμενης περιεκτικοτητας σε δραστικη ουσια και νεες χρησεις τους
CN112972405B (zh) * 2019-12-02 2022-12-27 北京兴源联合医药科技有限公司 一种他达拉非冻干口腔崩解片及其制备方法
CN112972404A (zh) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 一种西地那非冻干口腔崩解片及其制备方法
EP3928772A1 (de) 2020-06-26 2021-12-29 Algiax Pharmaceuticals GmbH Nanopartikuläre zusammensetzung
EP4243602A1 (de) * 2020-11-16 2023-09-20 Orcosa Inc. Verbesserte verwendung von cannabinoiden bei der behandlung von morbus alzheimer
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2023037394A1 (en) * 2021-09-13 2023-03-16 Amman Pharmaceutical Industries Company A pharmaceutical composition of sildenafil and a formulation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
WO2001035926A2 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
EP1289526A4 (de) * 2000-05-30 2005-03-16 Merck & Co Inc Agoniste des melanocortin-rezeptors
EP1301186A1 (de) * 2000-07-19 2003-04-16 Lavipharm Laboratories, Inc. Sildenafilcitrat-festdispersionen mit hoher wasserlöslichkeit
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP4776229B2 (ja) * 2002-07-16 2011-09-21 エラン ファーマ インターナショナル，リミティド 安定なナノ粒子活性物質の液体投与組成物
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil

Also Published As

Publication number Publication date
EP1658053B1 (de) 2008-02-27
JP4860469B2 (ja) 2012-01-25
WO2005013937A3 (en) 2005-06-16
EP1658053A2 (de) 2006-05-24
US20050042177A1 (en) 2005-02-24
JP2006528176A (ja) 2006-12-14
CA2533163A1 (en) 2005-02-17
ATE387186T1 (de) 2008-03-15
DE602004012117T2 (de) 2009-02-26
WO2005013937A2 (en) 2005-02-17
ES2302035T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
ATE387186T1 (de) Neue zusammensetzungen von sildenafil-freier base
ATE415946T1 (de) Neue metaxalon-zusammensetzungen
ATE419835T1 (de) Nystatin-nanopartikelzusammensetzungen
WO2005002542A3 (en) Nanoparticulate meloxican formulations
CY1113036T1 (el) Φαρμακοτεχνικες μορφες νανοσωματιδιων μεγεστρολης
SG161203A1 (en) Nanoparticulate tacrolimus formulations
EA200401556A1 (ru) Препараты на основе наночастиц фибрата
EA200702638A1 (ru) Стабильная композиция (рецептура) с наночастицами ацетаминофена
EA200701442A1 (ru) Композиции наночастиц кандесартана
ATE343376T1 (de) Nanopartikelzusammensetzungen von angiogeneseinhibitoren
ATE457718T1 (de) Sterile gefilterte nanoteilchen-formulierungen von budesonid mit tyloxapol als oberflächenstabilisator
EA200701107A1 (ru) Твердая фармацевтическая композиция, содержащая валсартан
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
ATE186208T1 (de) Verdicktes nichtabrasives körperwaschmittel
EA200701997A1 (ru) Композиция из наночастиц бисфосфоната
ATE385777T1 (de) Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren
MXPA05007635A (es) Composicion para la limpieza personal que contiene particulas de forma irregular y particulas esfericas.
ATE395042T1 (de) Darreichungsformen welche mikropartikel und treibgas enthalten
WO2007002315A3 (en) Nanoparticulate megestrol formulations
DE60331402D1 (de) Tintenzusammensetzung enthaltend Latexteilchenzusammensetzungen
ATE341606T1 (de) Natriumpercarbonatpartikel mit verbesserter lagerstabilit t
DE60226916D1 (de) Shampoo mit hohlen Teilchen
ATE359765T1 (de) Verringerung der teilchengrösse von bioaktiven verbindungen
EP1938803A3 (de) Formulierungen mit Nanoteilchen-Meloxican

Legal Events

Date Code Title Description
8364 No opposition during term of opposition